GABRA5 Gene

📖 Wiki Page

gene2239 wordssynced 2026-04-02

GABRA5 Gene

Introduction

...

GABRA5 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GABRA5 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRA5</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Gamma-Aminobutyric Acid Type A Receptor Alpha5 Subunit</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q12</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2568</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137142</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000118190</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P31644</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>456 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~52 kDa</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">RO4938581</td>
<td>α5 inverse agonist</td>
</tr>
<tr>
<td class="label">L-838417</td>
<td>α5 partial inverse agonist</td>
</tr>
<tr>
<td class="label">MRK-409</td>
<td>α5 inverse agonist</td>
</tr>
<tr>
<td class="label">PWZ-030</td>
<td>α5 inverse agonist</td>
</tr>
<tr>
<td class="label">Basmisanil</td>
<td>α5 inverse agonist</td>
</tr>
<tr>
<td class="label">Paradigm</td>
<td>GABRA5-/- Result</td>
</tr>
<tr>
<td class="label">Morris water maze</td>
<td>Faster learning</td>
</tr>
<tr>
<td class="label">Trace fear conditioning</td>
<td>Enhanced acquisition</td>
</tr>
<tr>
<td class="label">Elevated plus maze</td>
<td>Increased open arm time</td>
</tr>
<tr>
<td class="label">Pentylenetetrazol seizures</td>
<td>Lower threshold</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/bipolar" style="color:#ef9a9a">Bipolar</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">57 edges</a></td>
</tr>
</table>

The GABRA5 gene (Gamma-Aminobutyric Acid Type A Receptor Alpha5 Subunit) encodes a critical subunit of the GABA-A receptor that has garnered substantial attention in neuroscience research due to its pivotal role in memory, cognition, and its alterations in Alzheimer's disease (AD)[@kumar2019][@brawek2022]. The alpha5 subunit-containing GABA-A receptors (α5-GABA-A Rs) represent approximately 15-20% of all GABA-A receptors in the brain and are predominantly localized to extrasynaptic locations in the hippocampus and cortex, making them uniquely positioned to modulate neuronal excitability and memory consolidation processes[@caraiscos2004][@mohler2007].

The significance of GABRA5 in neurodegenerative disease research has grown substantially over the past two decades. While initial research focused on its role in learning and memory, more recent investigations have revealed important connections to Alzheimer's disease pathogenesis, age-related cognitive decline, and various neurological and psychiatric disorders[@mills2018][@scott2021]. The strategic targeting of α5-containing GABA-A receptors has emerged as a promising therapeutic approach for cognitive enhancement in aging and dementia populations.

GABRA5 is located on chromosome 15q12 and encodes a 456-amino acid protein that forms the distinctive pentameric structure of the GABA-A receptor. The gene has been the subject of extensive genetic association studies, with polymorphisms linked to various cognitive phenotypes, schizophrenia, and epilepsy[@george2012]. This comprehensive page explores the molecular biology, physiological functions, disease associations, and therapeutic targeting strategies for GABRA5.

Pathway / Interaction Diagram

Mermaid diagram (expand to render)

Gene Overview and Molecular Biology

Basic Gene Information

The GABRA5 gene spans approximately 23 kb and comprises 9 exons. The gene is subject to complex transcriptional regulation, with multiple transcription start sites and tissue-specific promoter elements governing its expression pattern. Alternative splicing produces variants that differ in their C-terminal intracellular domains, affecting trafficking and localization properties[@savic2010].

Protein Structure and Architecture

The GABA-A receptor alpha5 subunit follows the canonical Cys-loop receptor structure:

Extracellular N-terminal Domain:

Signal peptide for membrane targeting and secretion
Cys-loop motif: characteristic 13-amino acid loop with conserved disulfide-bonded cysteine residues
Six ligand-binding loops (A-F) that form the orthosteric binding site
Interface regions for GABA binding (between subunits)
Benzodiazepine binding pocket at the α-γ interface (when γ2 subunit present)[@rudolph2001]

Transmembrane Domain:

Four transmembrane helices (M1-M4) that traverse the lipid bilayer
M2 helix forms the ion channel pore with a characteristic sequence for chloride selectivity
M3-M4 intracellular loop contains major phosphorylation sites and trafficking motifs
Gating machinery linking agonist binding to channel opening[@savic2010]

Intracellular C-terminal Domain:

Large intracellular loop between M3 and M4 (approximately 150 amino acids)
Multiple serine and threonine residues for phosphorylation by PKA, PKC, and CK2
Sorting motifs for endoplasmic reticulum export and Golgi processing
Postsynaptic density (PSD) interaction domains for scaffolding proteins

Receptor Assembly and Stoichiometry

Native α5-GABA-A receptors form as pentameric assemblies:

Common Subunit Combinations:

α5β2γ2: Most prevalent in hippocampus (approximately 70% of α5 receptors)

α5β3γ2: Prominent in cortex

α5β2δ: Extrasynaptic receptors with tonic conductance

α5β2ε: Found in some cortical and hippocampal neurons

Extrasynaptic vs. Synaptic Receptors:

α5-containing receptors are predominantly extrasynaptic
Generate persistent tonic inhibitory currents
Respond to ambient GABA concentrations (0.1-1 μM)
Distinct from synaptic (phasic) inhibition mediated by α1, α2, and α3 subunits[@caraiscos2004]

Normal Physiological Function

Regional Expression Pattern

GABRA5 exhibits a highly restricted expression pattern:

High Expression Regions:

Hippocampus: CA1, CA2, CA3 pyramidal cell layers, dentate gyrus granule cell layer
Cerebral Cortex: Layer V pyramidal neurons, some layer II/III interneurons
Basal Ganglia: Striatum, nucleus accumbens
Olfactory System: Olfactory tubercle, piriform cortex
Temporal Lobe: Entorhinal cortex, perirhinal cortex[@mohler2007]

Cellular Localization:

Predominantly extrasynaptic on dendritic shafts
Minority population at synaptic junctions
Enriched in hippocampal CA1 stratum radiatum
Present on both pyramidal neurons and interneurons

Role in Memory and Learning

The α5-GABA-A receptor plays critical roles in memory processes:

Hippocampal Memory Circuitry:

Memory Encoding: α5 receptors modulate CA3-CA1 synaptic plasticity during encoding

Consolidation: Tonic inhibition affects systems consolidation during sleep

Retrieval: Hippocampal excitability during recall involves α5 function

Pattern Separation: Dendritic integration in dentate gyrus[@crestani2002]

Molecular Mechanisms:

Tonic Currents: α5-mediated I<sub>α5</sub> currents regulate neuronal excitability
Dendritic Integration: Modulation of back-propagating action potentials
Synaptic Plasticity: LTP and LTD modulation through inhibitory tone
Oscillations: Theta and gamma rhythm regulation in hippocampal networks[@liu2020]

Place Cell Function:

α5 receptors modulate place field stability
Influence grid cell activity in medial entorhinal cortex
Affect path integration mechanisms
Contribute to landmark-based navigation

Evidence from Knockout Studies:

GABRA5-/- mice show enhanced spatial learning in some paradigms
Reduced spatial discrimination in complex environments
Altered place cell firing properties
Impaired temporal context memory[@collinson2002]

Tonic Inhibition and Neuronal Excitability

Mechanism of Tonic Inhibition:

Ambient GABA: Low concentrations (0.1-1 μM) activate α5 receptors

Persistent Current: Continuous Cl⁻ influx reducing input resistance

Excitability Control: Dampens dendritic integration and action potential generation

Network Modulation: Affects hippocampal oscillations and synchrony[@caraiscos2004]

Physiological Significance:

Provides background inhibition preventing hyperexcitability
Regulates the balance of excitation and inhibition
Modulates signal-to-noise ratio in hippocampal circuits
Controls threshold for LTP induction

Role in Alzheimer's Disease

Expression Changes in AD

Hippocampal Alterations:

Marked reduction in α5 subunit expression in AD hippocampus
Progressive loss correlating with disease severity
Preferentially affects CA1 region
Loss of extrasynaptic receptors precedes synaptic loss[@kumar2019]

Molecular Mechanisms:

Transcriptional downregulation of GABRA5
Accelerated protein degradation
Altered subunit assembly stoichiometry
Post-translational modification changes

Clinical Correlations:

Cognitive decline severity correlates with α5 loss
Earlier onset AD shows more pronounced deficits
Rate of decline associated with receptor alterations

Tonic Inhibition Dysfunction

Consequences of α5 Loss:

Increased hippocampal neuronal excitability
Impaired homeostatic control of excitation
Enhanced susceptibility to excitotoxicity
Altered theta-gamma coupling[@brawek2022]

Circuit-Level Effects:

Dysregulated CA3-CA1 communication
Impaired pattern separation
Destabilized place cell representations
Disrupted memory consolidation

Therapeutic Implications

Rationale for α5 Targeting:

Cognitive Enhancement: α5 inverse agonists improve memory in preclinical models

Excitability Control: Modulating α5 may reduce hyperexcitability

Disease Modification: Protecting α5-expressing neurons from degeneration

Sleep Improvement: α5 modulators may improve sleep-dependent consolidation[@scott2021]

Clinical Trial Evidence:

RO4938581 (α5 inverse agonist): Showed cognitive benefits in Phase I/II trials
MRK-409: Demonstrated target engagement in human studies
L-838417: Provided proof-of-concept for cognitive enhancement[@atack2006]

GABAergic Dysfunction in AD Pathogenesis

Network-Level Changes:

Shift in excitation/inhibition balance toward excitation
Reduced inhibition creating network instability
Increased risk of epileptiform activity
Altered hippocampal oscillations during memory tasks

Interplay with Amyloid and Tau:

Amyloid-beta reduces α5-containing receptor function
Tau pathology affects GABAergic neuron survival
Synergistic effects on cognitive decline
Therapeutic targeting may address multiple pathways[@zhang2021]

Role in Other Neurological Disorders

Schizophrenia

Genetic Associations:

GABRA5 polymorphisms linked to schizophrenia risk
Copy number variants including GABRA5 in some patients
Epigenetic modifications affecting expression

Cognitive Deficits:

α5 receptor dysfunction contributes to working memory deficits
Hippocampal hyperactivity observed in schizophrenia patients
Reduced α5 expression in some postmortem studies

Therapeutic Potential:

α5 inverse agonists may improve cognitive symptoms
Combined antipsychotic and α5-targeted approaches
Potential for negative and cognitive symptom improvement[@george2012]

Epilepsy

Association with Seizure Disorders:

GABRA5 mutations in some patients with genetic epilepsy
α5-containing receptors as anti-seizure targets
Role in thalamic and hippocampal circuits

Anti-seizure Drug Actions:

Etomidate preferentially enhances α5 receptors
Clobazam has α5-selective actions
Loreclezole as α5-selective compound

Intellectual Disability

15q12 Deletion Syndrome:

Angelman syndrome involves GABRA5 hemizygosity
Prader-Willi syndrome includes GABRA5 deletion
Cognitive impairment correlates with dosage
Therapeutic approaches under investigation

Anxiety Disorders

Expression and Function:

α5 receptors in anxiety-related circuits
Anxiolytic effects of some α5 modulators
Genetic variants associated with anxiety phenotypes

Therapeutic Targeting:

α5-selective anxiolytics with reduced sedation
Combination approaches with SSRIs
Potential for treatment-resistant anxiety

Therapeutic Targeting Strategies

Inverse Agonists (Negative Allosteric Modulators)

Mechanism:

Reduce baseline receptor activity below constitutive level
Increase neuronal excitability by decreasing tonic inhibition
Enhance memory encoding and consolidation
Particularly effective in contexts with high baseline α5 activity

Clinical Candidates:

Therapeutic Applications:

Alzheimer's disease cognitive enhancement
Age-related cognitive decline
Schizophrenia cognitive symptoms
Memory impairment in psychiatric disorders

Positive Allosteric Modulators

Rationale:

Enhance α5 receptor function to increase tonic inhibition
Reduce neuronal hyperexcitability
May protect against excitotoxicity
Potential for neuroprotective effects[@rousseau2023]

Development Status:

PWZ-028: Preclinical development
Multiple compounds under investigation
Focus on reducing seizure risk (inverse agonists showed pro-convulsant effects)

Selective Modulators

TPA-023 (discontinued):

α2/α3/α5 selective partial agonist
Anxiolytic with reduced sedation
Development halted due to preclinical toxicity

Novel Approaches:

Allosteric modulators with biased signaling
State-selective compounds
Photopharmacological tools for research

Gene Therapy and Molecular Approaches

Viral Vector Delivery:

AAV-mediated GABRA5 overexpression
Hippocampal targeting via stereotactic injection
Potential for sustained therapeutic benefit

CRISPR-Based Strategies:

Enhancement of endogenous GABRA5 expression
Correction of disease-causing variants
Allele-specific approaches

Antisense Oligonucleotides:

Modulation of GABRA5 expression
Selective reduction of pathological isoforms

Animal Models and Research Findings

Knockout Mouse Studies

GABRA5-/- Phenotype:

Viable and fertile with minimal developmental abnormalities
Enhanced learning in some behavioral paradigms (Morris water maze, trace conditioning)
Reduced anxiety in elevated plus maze and light-dark tests
Increased seizure susceptibility to various convulsants
Altered hippocampal plasticity with enhanced LTP

Behavioral Findings: Molecular Changes:

Compensatory upregulation of other α subunits
Altered GABAergic network properties
Changed phosphorylation of learning-related proteins

Transgenic Models

α5 Overexpression:

Impaired spatial memory
Increased anxiety-like behavior
Reduced LTP in CA1

Humanized Mouse Models:

Expressing human GABRA5 variants
Alzheimer disease model crosses
Demonstrating therapeutic target validation

Disease Model Studies

5xFAD Alzheimer's Model:

Progressive loss of α5 receptors
Spatial memory deficits correlating with α5 loss
Therapeutic benefit from α5 inverse agonists

Age-Related Cognitive Decline:

Natural aging reduces α5 expression
Inverse agonist treatment improves performance
Reversal of age-related deficits

Expression Regulation and Genetic Variants

Transcriptional Regulation

Promoter Elements:

Multiple transcription start sites
Neuron-specific expression via REST and neuron-restrictive silencer element
Activity-dependent regulation via cAMP response elements
Hormonal modulation (estrogen response elements)

Epigenetic Modifications:

DNA methylation in promoter region
Histone acetylation effects on expression
Age-related epigenetic changes

Polymorphisms and Genetic Variants

Common Variants:

SNPs in coding and regulatory regions
Association with cognitive phenotypes
Risk variants for schizophrenia
Effects on treatment response

Rare Variants:

Pathogenic mutations in epilepsy
Copy number variations in neurodevelopmental disorders
Variant effects on receptor function

Interactions with Other Proteins

Scaffold and Clustering Proteins

Gephyrin:

Primary clustering protein for GABA-A receptors
Direct interaction with α5 cytoplasmic loop
Regulates postsynaptic localization
Links to cytoskeletal elements

Collybistin:

Membrane-associated guanylate kinase (MAGUK) protein
Gephyrin interaction and clustering
Required for some α5-containing receptor clusters

Signaling Molecules

Protein Kinases:

PKA phosphorylation of serine residues
PKC modulation of receptor trafficking
CK2 phosphorylation affecting desensitization
Casein kinase 1 regulate membrane insertion

Phosphatases:

PP1 and PP2A dephosphorylation
Modulation of receptor function
Activity-dependent regulation

Ion Channel Partners

β Subunits:

GABRB2 (β2): Primary partner in hippocampal receptors
GABRB3: Alternative β subunit

γ and δ Subunits:

GABRG2 (γ2): Synaptic receptor formation
GABRD (δ): Extrasynaptic receptors with high sensitivity

Future Directions and Research Gaps

Unresolved Questions

Temporal Dynamics: How does α5 expression change across disease progression?

Cell-Type Specificity: What defines α5-expressing neuron populations?

Network Effects: How does α5 modulation affect hippocampal-cortical communication?

Emerging Research Areas

Neuroimaging: PET ligands for α5 receptors in human brain

Biomarkers: Peripheral markers of α5 function

Personalized Medicine: Genetic stratification for treatment selection

Therapeutic Development Priorities

Safety optimization: Reducing seizure risk with inverse agonists

Efficacy enhancement: Combination therapies for AD

Disease modification: Neuroprotective approaches

External Links

[NCBI Gene: GABRA5](https://www.ncbi.nlm.nih.gov/gene/2568)
[UniProt: P31644](https://www.uniprot.org/uniprot/P31644)
[OMIM: 137142](https://www.omim.org/entry/137142)
[Ensembl: ENSG00000118190](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118190)
[GeneCards: GABRA5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GABRA5)
[IUPHAR: GABA-A α5](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2043)

Pathway Diagram

The following diagram shows the key molecular relationships involving GABRA5 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

GABRA5 Gene

GABRA5 Gene

Introduction

GABRA5 Gene

Introduction

Pathway / Interaction Diagram

Gene Overview and Molecular Biology

Basic Gene Information

Protein Structure and Architecture

Receptor Assembly and Stoichiometry

Normal Physiological Function

Regional Expression Pattern

Role in Memory and Learning

Spatial Navigation and Place Cells

Tonic Inhibition and Neuronal Excitability

Role in Alzheimer's Disease

Expression Changes in AD

Tonic Inhibition Dysfunction

Therapeutic Implications

GABAergic Dysfunction in AD Pathogenesis

Role in Other Neurological Disorders

Schizophrenia

Epilepsy

Intellectual Disability

Anxiety Disorders

Therapeutic Targeting Strategies

Inverse Agonists (Negative Allosteric Modulators)

Positive Allosteric Modulators

Selective Modulators

Gene Therapy and Molecular Approaches

Animal Models and Research Findings

Knockout Mouse Studies

Transgenic Models

Disease Model Studies

Expression Regulation and Genetic Variants

Transcriptional Regulation

Polymorphisms and Genetic Variants

Interactions with Other Proteins

Scaffold and Clustering Proteins

Signaling Molecules

Ion Channel Partners

Future Directions and Research Gaps

Unresolved Questions

Emerging Research Areas

Therapeutic Development Priorities

See Also

External Links

Pathway Diagram